Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study

Fertility and Sterility

Volumn 107, Issue 1, 2017, Pages 253-260.e1

  Elkind Hirsch, Karen E ^a   Paterson, Martha S ^a   Seidemann, Ericka L ^a   Gutowski, Hanh C ^a  

^a WOMAN S HOSPITAL   (United States)

Author keywords

Dipeptidyl peptidase 4 inhibitor; polycystic ovary syndrome; prediabetic hyperglycemia; saxagliptin

Indexed keywords

ANDROGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; PRASTERONE SULFATE; SAXAGLIPTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; ADAMANTANE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DELAYED RELEASE FORMULATION; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG COMBINATION; GLUCOSE BLOOD LEVEL;

ADULT; ANDROGEN BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; EXTENDED RELEASE FORMULATION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; MENSTRUAL CYCLE; MONOTHERAPY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST TO HEIGHT RATIO; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; METABOLISM; OBESITY; PATHOPHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; PREDIABETIC STATE; TIME FACTOR; YOUNG ADULT;

ADAMANTANE; ADIPOSITY; ADOLESCENT; ADULT; ANDROGENS; BIOMARKERS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MENSTRUAL CYCLE; METFORMIN; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; PREDIABETIC STATE; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85006060179     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2016.09.023     Document Type: Conference Paper

References (40)

1. 1 Hull, M.G., Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1 (1987), 235–245.
2. 2 Knochenhauer, E.S., Key, T.J., Kahsar-Miller, M., Waggoner, W., Boots, L.R., Azziz, R., Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998), 3078–3082.
3. 3 Azziz, R., Woods, K.S., Reyna, R., Key, T.J., Knochenhauer, E.S., Yildiz, B.O., The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004), 2745–2749.
4. 4 National Institutes of Health. National Institutes of Health Evidence-based Methodology Workshop on Polycystic Ovary Syndrome, December 3-5 2012. Available at: https://prevention.nih.gov/docs/programs/pcos/finalreport.pdf. Accessed June 1, 2016.
5. 5 Gambineri, A., Pelusi, C., Vicennati, V., Pagotto, U., Pasquali, R., Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26 (2002), 883–896.
6. 6 Morgan, C., Jenkins-Jones, S., Currie, C., Rees, D.A., Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched reference controls: a retrospective, observational study. J Clin Endocrinol Metab 97 (2012), 3251–3260.
7. 7 Ehrmann, D.A., Barnes, R.B., Rosenfield, R.L., Cavaghan, M.K., Imperial, J., Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999), 141–146.
8. 8 Cibula, D., Cífková, R., Fanta, M., Poledne, R., Zivny, J., Skibová, J., Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 15 (2000), 785–789.
9. 9 Diamanti Kandarakis, E., Papavassiliou, A.G., Kandarakis, S.A., Chrousos, G.P., Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 18 (2007), 280–285.
10. 10 Glueck, C.J., Papanna, R., Wang, P., Goldenberg, N., Sieve-Smith, L., Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52 (2003), 908–915.
11. 11 Legro, R.S., Kunselman, A.R., Dodson, W.C., Dunaif, A., Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999), 165–169.
12. 12 Dunaif, A., Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 18 (1997), 774–800.
13. 13 Dunaif, A., Segal, K.R., Futterweit, W., Dobrjansky, A., Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989), 1165–1174.
14. 14 Dunaif, A., Finegood, D.T., Beta-cell dysfunction independent of obesity and glucose tolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81 (1996), 942–947.
15. 15 O'Meara, N.M., Blackman, J.D., Ehrmann, D.A., Barnes, R.B., Jaspan, J.B., Rosenfield, R.L., et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76 (1993), 1241–1247.
16. 16 Ehrmann, D.A., Sturis, J., Byrne, M.M., Karrison, T., Rosenfield, R.L., Polonsky, K.S., Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 96 (1995), 520–527.
17. 17 Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17 (2013), 819–837.
18. 18 Janardhan, S., Sastry, G.N., Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment. Curr Drug Targets 15 (2014), 600–621.
19. 19 Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
20. 20 Nauck, M.A., Heimesaat, M.M., Behle, K., Holst, J.J., Nauck, M.S., Ritzel, R., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87 (2002), 1239–1246.
21. 21 Elkind-Hirsch, K.E., Marrioneaux, O., Bhushan, M., Vernor, D., Bhushan, R., Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endo Metab 93 (2008), 2670–2678.
22. 22 Abdul-Ghani, M.A., Tripathy, D., DeFronzo, R.A., Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29 (2006), 1130–1139.
23. 23 Mathur, R.S., Moody, L.O., Landgrebbe, S., Williamson, H.O., Plasma androgens and sex hormone binding globulin in the evaluation of hirsute patients. Fertil Steril 35 (1981), 29–35.
24. 24 American Diabetes Association. Position statement. Standards of medical care in diabetes-2013. Diabetes Care 36:Suppl 1 (2013), 4–10.
25. 25 McLaughlin, T., Abbasi, F., Cheal, K., Chu, J., Lamendola, C., Reaven, G., Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139 (2003), 802–809.
26. 26 Ashwell, M., Cole, T.J., Dixon, A.K., Ratio of waist circumference to height is strong predictor of intra-abdominal fat. Br Med J 313 (1996), 559–560.
27. 27 Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
28. 28 Matsuda, M., DeFronzo, R., Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999), 1462–1470.
29. 29 Wareham, N.J., Phillips, D.I., Byrne, C.D., Hales, C.N., The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med, 12, 1995, 931.
30. 30 Kahn, S.E., Prigeon, R.L., McCulloch, D.K., Boyko, E.J., Bergman, R.N., Schwartz, M.W., et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42 (1993), 1663–1672.
31. 31 Ahren, B., Pacini, G., Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess β cell function in clinical studies. Eur J Endocrinol 150 (2004), 97–104.
32. 32 Retnakaran, R., Shen, S., Hanley, A.J., Vuksan, V., Hamilton, J.K., Zinman, B., Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 16 (2008), 1901–1907.
33. 33 DeUgarte, C.M., Bartolucci, A.A., Azziz, R., Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83 (2005), 1454–1460.
34. 34 Crave, J.C., Fimbel, S., Lejeune, H., Cugnardey, N., Déchaud, H., Pugeat, M., Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 80 (1995), 2057–2062.
35. 35 Ehrmann, D.A., Cavaghan, M.K., Imperial, J., Sturis, J., Rosenfield, R.L., Polonsky, K.S., Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997), 524–530.
36. 36 Messer, C., Boston, R., Leroith, D., Geer, E., Miller, J., Messer, M., et al. Pancreatic ß-cell dysfunction in polycystic ovary syndrome: the role of metformin. Endocrin Pract 18 (2012), 685–693.
37. 37 Karagiannis, T., Paschos, P., Paletas, K., Matthews, D.R., Tsapas, A., Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ, 344, 2012, e1369.
38. 38 Rosenstock, J., Baron, M.A., Camisasca, R.P., Cressier, F., Couturier, A., Dejager, S., Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 9 (2007), 175–185.
39. 39 Bruno, R.V., de Avila, M.A., Neves, F.B., Nardi, A.E., Crespo, C.M., Sobrinho, A.T., Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference. Fertil Steril 88 (2007), 510–512.
40. 40 Lord, J., Thomas, R., Fox, B., Acharya, U., Wilkin, T., The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome—a randomised, double-blind, placebo-controlled trial. Br J Ob Gyn 113 (2006), 817–824.